{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Netarsudil+Ophthalmic",
    "query": {
      "intervention": "Netarsudil Ophthalmic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Netarsudil+Ophthalmic&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T18:21:50.803Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07209410",
      "title": "Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate Ophthalmic 0.025%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2025-11-01",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209410"
    },
    {
      "nct_id": "NCT06441643",
      "title": "Next Generation Rocklatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AR-17043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "PG043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "AR-17043 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 426,
      "start_date": "2024-09-04",
      "completion_date": "2025-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 12,
      "location_summary": "Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441643"
    },
    {
      "nct_id": "NCT02207621",
      "title": "Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 756,
      "start_date": "2014-07",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207621"
    },
    {
      "nct_id": "NCT01528787",
      "title": "Study of AR-13324 in Patients With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 85,
      "start_date": "2012-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-18",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 11,
      "location_summary": "Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528787"
    },
    {
      "nct_id": "NCT07048886",
      "title": "Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Rocklatan (netarsudil 0.02% and latanoprost 0.005%)",
          "type": "DRUG"
        },
        {
          "name": "Systane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for Sight Las Vegas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2025-07-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07048886"
    },
    {
      "nct_id": "NCT02674854",
      "title": "Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "PG324 Ophthalmic Solution 0.02%/0.005%",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil (AR-13324) ophthalmic solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost ophthalmic solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 750,
      "start_date": "2016-02",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2019-05-21",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02674854"
    },
    {
      "nct_id": "NCT07325240",
      "title": "24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-11-21",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07325240"
    },
    {
      "nct_id": "NCT03233308",
      "title": "Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma or Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-10-20",
      "completion_date": "2018-04-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Durham, North Carolina",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233308"
    },
    {
      "nct_id": "NCT02246764",
      "title": "Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "19 Years to 99 Years"
      },
      "enrollment_count": 93,
      "start_date": "2014-09",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246764"
    },
    {
      "nct_id": "NCT04981886",
      "title": "Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Normal Tension Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Salus University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "21 Years to 89 Years"
      },
      "enrollment_count": 115,
      "start_date": "2021-08",
      "completion_date": "2022-08",
      "has_results": false,
      "last_update_posted_date": "2021-08-06",
      "last_synced_at": "2026-09-04T18:21:50.803Z",
      "location_count": 1,
      "location_summary": "Vestal, New York",
      "locations": [
        {
          "city": "Vestal",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04981886"
    }
  ]
}